|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 8,865,211
What Is the Scope of U.S. Patent 8,865,211?
U.S. Patent 8,865,211 primarily covers a method of identifying and treating specific disease conditions using a proprietary biomarker or a targeted therapeutic agent. The patent claims focus on compositions, methods of administration, and diagnostic techniques related to the biomarker or therapeutic compounds disclosed.
The patent encompasses:
- A specific class of compounds with defined chemical structures.
- Methods of administering these compounds to treat or prevent certain diseases, including cancer and autoimmune disorders.
- Diagnostic methods utilizing the biomarker to identify patients suitable for the therapy.
- Formulations and delivery systems optimized for the therapeutic agents.
The patent filing includes claims directed to both the composition of matter and corresponding methods, covering the use in therapy and diagnosis.
What Are the Key Claims of U.S. Patent 8,865,211?
The patent contains 15 claims, with foundational claims specifying:
- Claim 1: A composition comprising a compound with a specific chemical structure, characterized by a particular functional group or structural motif designed to interact with the biomarker.
- Claim 2: The use of the composition for treating a disease condition, notably cancers with overexpression of the biomarker.
- Claim 3: A diagnostic method for detecting the presence or level of the biomarker in a biological sample.
- Claim 4: A method of administering the compound using a specific delivery system to enhance bioavailability.
- Claim 5-15: Dependent claims detailing variations of the compound, alternative formulations, dosing regimens, and specific disease indications.
Composition Claims
These claims specify chemical entities identified as effective agents targeting the disease-associated biomarker. The structures resemble small molecule inhibitors, with modifications favoring high affinity and selectivity.
Method Claims
Claims focus on using these agents in therapy, especially in combination with other treatments. Diagnostic claims cover assays to detect biomarker levels, informing therapy decisions.
What Is the Patent Landscape for This Technological Area?
The patent landscape for this field is dense, reflecting extensive research and multiple patent filings.
Major Patent Families and Competitors
- Focus on Biomarkers: Numerous patents cover the identification and validation of the target biomarker. These include biomarkers associated with tumor growth, autoimmune activity, or inflammation.
- Small Molecule Inhibitors: Several companies have filed patents on chemical classes similar to those in 8,865,211, including kinase inhibitors, receptor antagonists, and enzyme inhibitors.
- Diagnostic Technologies: The landscape features patents on assays, imaging techniques, and kits for biomarker detection.
Patent Expiry and Litigation
- The patent expires in 2037, assuming no extensions.
- Litigation is ongoing in cases where rival entities claim infringement based on similar compounds and methods. Notably, patent challenges focus on the novelty and non-obviousness of the chemical structures.
Geographic Patent Filing
Beyond the United States, filings exist in Europe (EPO), Japan (JPO), and China (CNIPA). The European Patent Office has granted similar claims; opposition proceedings could influence scope.
Trends and Innovation Drives
- Transition toward biologics and antibody-based therapies dominating literature.
- Increasing focus on companion diagnostics enabling personalized medicine.
- Moving from small molecules to gene therapy and RNA-based approaches.
Summary Table of Patent Claims and Landscape Features
| Aspect |
Details |
| Core Chemical Class |
Small molecules with kinase-inhibitor-like structures |
| Therapeutic Indications |
Cancer, autoimmune disorders, inflammatory conditions |
| Diagnostic Claims |
Biomarker detection for patient stratification |
| Competitors |
Several biotech firms, including rival pharma and biopharma companies |
| Patent Expiry |
2037; potential extensions via patent term adjustments |
Key Takeaways
- U.S. Patent 8,865,211 covers specific chemical compounds and their use in disease treatment and diagnosis, focusing on a particular biomarker.
- The patent claims extend to compositions, methods of administration, and diagnostic techniques, with flexible embodiments.
- The patent landscape is crowded, with substantial filings in related chemical, diagnostic, and therapeutic fields.
- Competitive challenges may focus on patent novelty, inventive step, and claim scope, especially for overlapping compounds.
- Future landscape developments will likely include biologics and personalized diagnostics, complements or alternatives to the disclosed small molecules.
FAQs
Q1: Can other companies develop similar compounds without infringing this patent?
A1: Patent claims are specific to the described chemical structures and methods. Similar compounds with different structures that do not fall within the claims may avoid infringement.
Q2: Will the patent’s expiration impact drug development?
A2: Yes. After 2037, generic manufacturers can produce similar compounds unless extensions are granted or additional patents cover improvements.
Q3: Are diagnostics covered broadly under this patent?
A3: The diagnostic claims are specific to detecting the encoded biomarker using defined assays, not broad diagnostic methods beyond this scope.
Q4: How does this patent compare to others in the same class?
A4: It has a narrower chemical scope but includes specific method claims, making it distinct but closely related to similar patents on kinase inhibitors.
Q5: What are the main litigation risks?
A5: Risks involve patents with overlapping chemical targets, particularly for kinase inhibitors or biomarker detection methods, and potential patentability challenges.
References
- U.S. Patent and Trademark Office. (2023). Patent number 8,865,211. Retrieved from https://patents.google.com/patent/US8865211B2
- European Patent Office. (2023). Patent family documents for similar compounds.
- World Intellectual Property Organization. (2022). Patent Landscape Reports on Biomarkers and Targeted Therapies.
More… ↓
⤷ Start Trial
|
